Broadwood Partners Amends Lineage Cell Therapeutics Stake

TL;DR

Broadwood Partners filed a 13D/A amendment for Lineage Cell Therapeutics, Inc. (ticker LCTX).

AI Summary

Broadwood Partners, L.P. filed an amendment (No. 27) to its Schedule 13D on November 21, 2024, regarding its holdings in Lineage Cell Therapeutics, Inc. The filing indicates a change in the beneficial ownership of the company's common shares. Broadwood Partners, L.P. is based in New York and is involved in investment management.

Why It Matters

This amendment signals a potential shift in significant shareholder positions, which could influence market perception and trading activity for Lineage Cell Therapeutics.

Risk Assessment

Risk Level: medium — Schedule 13D filings often indicate significant investor activity, which can lead to increased volatility.

Key Players & Entities

• Broadwood Partners, L.P. (company) — Filing entity
• Lineage Cell Therapeutics, Inc. (company) — Subject company
• Neal C. Bradsher (person) — Contact person for Broadwood Capital, Inc.
• Broadwood Capital, Inc. (company) — Associated entity with filing

FAQ

Key Financial Figures

• $6,000,000 — offering for a total purchase price of $6,000,000, or $0.76 per Share and accompanying Co
• $0.76 — total purchase price of $6,000,000, or $0.76 per Share and accompanying Common Warra

Filing Documents

• d11534381_13d-a.htm (SC 13D/A) — 100KB
• 0000919574-24-006855.txt ( ) — 102KB

SIGNATURES

SIGNATURES After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: November 21, 2024 Broadwood Partners, L.P.* By: Broadwood Capital, Inc. By: /s/ Neal C. Bradsher Name: Neal C. Bradsher Title: President Broadwood Capital, Inc. * By: /s/ Neal C. Bradsher Name: Neal C. Bradsher Title: President /s/ Neal C. Bradsher Neal C. Bradsher * * This Reporting Person disclaims beneficial ownership over the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001). Exhibit A JOINT FILING AGREEMENT The undersigned agree that this Amendment No. 27 to Schedule 13D, dated November 21, 2024, relating to the Common Shares, no par value, of Lineage Cell Therapeutics, Inc. shall be filed on behalf of the undersigned. Dated: November 21, 2024 Broadwood Partners, L.P. By: Broadwood Capital, Inc. By: /s/ Neal C. Bradsher Name: Neal C. Bradsher Title: President Broadwood Capital, Inc. By: /s/ Neal C. Bradsher Name: Neal C. Bradsher Title: President /s/ Neal C. Bradsher Neal C. Bradsher

View Full Filing

View this SC 13D/A filing on SEC EDGAR